3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Leukemia, Myeloid, Acute
6
Solid Tumor
2
Myelodysplastic Syndromes
2
Lymphoma, Non-Hodgkin
2
Colorectal Neoplasms
2
Urinary Bladder Neoplasms
1
Unresectable Colorectal Cancer
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Myeloid Malignancies
1
Multiple Myeloma
1
Lymphoma, Large B-Cell, Diffuse
1
Hematologic Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
75
Carboplatin
46
Paclitaxel
44
130-nm albumin-bound paclitaxel
35
Gemcitabine
34
Cyclophosphamide
23
Capecitabine
22
Nivolumab
21
Albumin-Bound Paclitaxel
21
atezolizumab
20
sacituzumab govitecan
14
spartalizumab
13
Doxorubicin
11
olaparib
9
Cisplatin
9
Bevacizumab
9
eribulin
8
fludarabine
7
durvalumab
7
avelumab
7
Injections
7
Fulvestrant
7
Fluorouracil
7
Vinorelbine
6
Leucovorin
6
Docetaxel
6
iniparib
5
budigalimab
5
Ipilimumab
5
Epirubicin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Triple Negative Breast Neoplasms
×
magrolimab
×
Clear all
NCT04958785
2025-11-04
ELEVATE TNBC
Gilead Sciences
Phase 2
Terminated
92 enrolled
27 charts